STOCK TITAN

Trevena Inc - TRVN STOCK NEWS

Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.

Trevena Inc (NASDAQ: TRVN) is a clinical-stage biopharmaceutical pioneer developing novel therapies for central nervous system disorders and pain management through advanced GPCR targeting. This page provides investors and industry professionals with a comprehensive repository of Trevena news, including clinical trial updates, regulatory milestones, and research developments.

Access timely updates on Trevena's innovative pipeline, including OLINVYK™ (oliceridine) for acute pain and investigational candidates like TRV045 for neuropathic pain. Track progress across preclinical studies, FDA communications, and strategic partnerships that shape the company's trajectory in neuroscience therapeutics.

Key content includes earnings reports, patent filings, scientific presentations, and analyses of Trevena's biased ligand platform—a Nobel Prize-influenced approach to minimizing opioid-related side effects. All materials are curated to support informed decision-making without promotional bias.

Bookmark this page for centralized access to Trevena's latest advancements in non-opioid pain management and CNS disorder treatments. Regularly updated to reflect new developments in GPCR-focused drug discovery and clinical-stage biopharma innovation.

Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) announced promising results of TRV045 in nonclinical models of neuropathic pain, targeting the S1P1 receptor without causing lymphopenia. The poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology discussed the potential utility of TRV045 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) and its collaboration with the NIH to evaluate TRV045 for epilepsy and nonopioid pain treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
Rhea-AI Summary
Trevena Inc. (Nasdaq: TRVN) has secured a national group purchasing agreement for OLINVYK with Premier, Inc., effective December 1, 2023. Premier members now have the option to benefit from special pricing and terms pre-negotiated for OLINVYK, a significant development for the company's commercialization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) announced the acceptance of the RELIEVE study abstract at the 2024 ABA Annual Meeting. The study focused on evaluating OLINVYK for patients with acute burn injuries. Results will be presented in April 2024. Dr. David Hill led the single-center trial, comparing OLINVYK with other IV opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) reported promising proof-of-concept data for TRV045 studies, favorable safety and tolerability topline data, and a strengthened balance sheet with a $15 million R-Bridge tranche. TRV045 demonstrated CNS target engagement and encouraging overall results in two proof-of-concept studies. Three OLINVYK abstracts were presented at ASA. The Company received a $15 million tranche from ex-US royalty-based financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Summary
Trevena, Inc. (Nasdaq: TRVN) to Release Third Quarter 2023 Financial Results and Host Conference Call & Webcast at 8:00 a.m. ET. The company will discuss financial performance and future prospects, featuring remarks by key executives and a renowned medical expert. Investors can access the webcast via the provided links.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
-
Rhea-AI Summary
Trevena, Inc. completes initial analysis of OLINVYK respiratory monitoring data from VOLITION study, to be presented at ASA meeting in October. No drug-related serious adverse events (SAEs) or deaths reported. Study shows potential positive impact on respiratory outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
Rhea-AI Summary
Trevena, Inc. receives $15 million tranche from ex-US royalty-based financing triggered by first commercial sale of OLINVYK in China. New respiratory data from VOLITION study expected in 3Q 2023. Three OLINVYK abstracts accepted for presentation at ASA Meeting in 4Q 2023. Company to participate in HC Wainwright conference. Conference call on September 6 to discuss TRV045 data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Summary
Trevena, Inc. announces preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1. Data shows statistically significant analgesic effect in capsaicin-induced model of neuropathic pain and evidence of CNS activity as measured by EEG power spectral analysis. Full safety and tolerability data expected in early 4Q 2023. Company to hold conference call on September 6 at 8 a.m. Eastern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Trevena Inc

Nasdaq:TRVN

TRVN Rankings

TRVN Stock Data

1.27M
850.11k
0.49%
9.99%
6.96%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHESTERBROOK